Halozyme to Report Second Quarter 2025 Financial and Operating Results

Core Insights - Halozyme Therapeutics, Inc. will release its second quarter 2025 financial and operating results on August 5, 2025, after market close [1] - A conference call to discuss the results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, accessible via pre-registration [1] - A live webcast and replay of the conference call will be available on Halozyme's corporate website [2] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes through its ENHANZE® drug delivery technology [3] - The proprietary enzyme rHuPH20 facilitates subcutaneous delivery of drugs, improving patient experience by enabling rapid delivery and reducing treatment burden [3] - The technology has been utilized in over one million patient lives across ten commercialized products in more than 100 global markets, licensed to major pharmaceutical companies including Roche, Takeda, and Pfizer [3] - Halozyme also develops drug-device combination products using advanced auto-injector technologies, aimed at improving convenience, reliability, and patient adherence [4] - The company has two proprietary commercial products, Hylenex® and XYOSTED®, along with partnerships for product development with Teva Pharmaceuticals and McDermott Laboratories [4] - Halozyme is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN, which also houses its operations facility [5]